Zenas BioPharma (ZBIO) Other Accumulated Expenses (2023 - 2026)

Zenas BioPharma's Other Accumulated Expenses history runs 4 years deep, the most recent figure standing at $936000.0 for Q1 2026.

• In Q1 2026, Other Accumulated Expenses rose 143.75% year-over-year to $936000.0; the TTM figure through Mar 2026 stood at $936000.0 (up 143.75% YoY), while the FY2025 annual figure was $870000.0, up 249.4% from the prior year.
• Other Accumulated Expenses was $936000.0 for Q1 2026 at Zenas BioPharma, up from $870000.0 in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $936000.0 in Q1 2026 to a low of $106000.0 in Q4 2023.
• Historically, Other Accumulated Expenses has averaged $495625.0 across 4 years, with a median of $446000.0 in 2025.
• Biggest YoY gain for Other Accumulated Expenses was 249.4% in 2025; the steepest drop was 74.7% in 2025.
• A 4-year view of Other Accumulated Expenses shows it stood at $106000.0 in 2023, then surged by 134.91% to $249000.0 in 2024, then surged by 249.4% to $870000.0 in 2025, then gained by 7.59% to $936000.0 in 2026.
• The last three Other Accumulated Expenses figures came in at $936000.0 (Q1 2026), $870000.0 (Q4 2025), and $580000.0 (Q3 2025), per Business Quant data.